Effect of Transporter and DNA Repair Gene Polymorphisms to Lung Cancer Chemotherapy Toxicity

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Sep 12

PMID 26358256

Citations 11

Authors

Juan Chen

Lin Wu

Ying Wang

Jiye Yin

Xiangping Li

Zhan Wang

Huihua Li

Ting Zou

Chenyue Qian

Chuntian Li

Wei Zhang

Honghao Zhou

Zhaoqian Liu

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the first leading cause of cancer deaths. Chemotherapy toxicity is one of factors that limited the efficacy of platinum-based chemotherapy in lung cancer patients. Transporters and DNA repair genes play critical roles in occurrence of platinum-based chemotherapy toxicity. To investigate the relationships between transporter and DNA repair gene polymorphisms and platinum-based chemotherapy toxicity in lung cancer patients, we selected 60 polymorphisms in 14 transporters and DNA repair genes. The polymorphisms were genotyped in 317 lung cancer patients by Sequenom MassARRAY. Logistic regression was performed to estimate the association of toxicity outcome with the polymorphisms by PLINK. Our results showed that polymorphisms of SLC2A1 (rs3738514, rs4658, rs841844) were significantly related to overall toxicity. XRCC5 (rs1051685, rs6941) and AQP2 (10875989, rs3759125) polymorphisms were associated with hematologic toxicity. AQP2 polymorphisms (rs461872, rs7305534) were correlated with gastrointestinal toxicity. In conclusion, genotypes of these genes may be used to predict the platinum-based chemotherapy toxicity in lung cancer patients.

Citing Articles

Influence of Genetic Polymorphisms on the Age at Cancer Diagnosis in a Homogenous Lynch Syndrome Cohort of Individuals Carrying the :c.1528C>T South African Founder Variant.

Ndou L, Chambuso R, Algar U, Goldberg P, Boutall A, Ramesar R Biomedicines. 2024; 12(10).

PMID: 39457514 PMC: 11505229. DOI: 10.3390/biomedicines12102201.

Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review.

Zheng Y, Tang M, Deng Z, Cai P Front Pharmacol. 2024; 15:1445328.

PMID: 39234108 PMC: 11371761. DOI: 10.3389/fphar.2024.1445328.

Impact of genetic variants in the solute carrier () genes encoding drug uptake transporters on the response to anticancer chemotherapy.

Marin J, Serrano M, Herraez E, Lozano E, Ortiz-Rivero S, Perez-Silva L Cancer Drug Resist. 2024; 7:27.

PMID: 39143954 PMC: 11322974. DOI: 10.20517/cdr.2024.42.

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

Zou T, Liu J, Qin Q, Guo J, Zhou W, Li X Biomedicines. 2023; 11(12).

PMID: 38137354 PMC: 10741124. DOI: 10.3390/biomedicines11123133.

The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients.

He J, Wang Z, Zou T, Wang Y, Li X, Chen J Pharmgenomics Pers Med. 2022; 15:817-825.

PMID: 36131844 PMC: 9484078. DOI: 10.2147/PGPM.S375284.

References

Giachino D, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G . Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res. 2007; 13(10):2876-81. DOI: 10.1158/1078-0432.CCR-06-2543. View

Martin L, Hamilton T, Schilder R . Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008; 14(5):1291-5. DOI: 10.1158/1078-0432.CCR-07-2238. View

Lebwohl D, Canetta R . Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1999; 34(10):1522-34. DOI: 10.1016/s0959-8049(98)00224-x. View

Knepper M, Wade J, Terris J, Ecelbarger C, Marples D, Mandon B . Renal aquaporins. Kidney Int. 1996; 49(6):1712-7. DOI: 10.1038/ki.1996.253. View

Li X, Yin J, Wang Y, He H, Li X, Gong W . The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumour Biol. 2014; 35(8):8259-65. DOI: 10.1007/s13277-014-2072-0. View

De Grandis E, Stagnaro M, Biancheri R, Giannotta M, Gobbi G, Traverso M . Lack of SLC2A1 (glucose transporter 1) mutations in 30 Italian patients with alternating hemiplegia of childhood. J Child Neurol. 2012; 28(7):863-6. DOI: 10.1177/0883073812452789. View

Holmes R . The role of renal water channels in health and disease. Mol Aspects Med. 2012; 33(5-6):547-52. PMC: 6900978. DOI: 10.1016/j.mam.2012.01.001. View

Hall M, Okabe M, Shen D, Liang X, Gottesman M . The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2007; 48:495-535. DOI: 10.1146/annurev.pharmtox.48.080907.180426. View

Song K, Li M, Xu X, Xuan L, Huang G, Song X . HIF-1α and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia. Asian Pac J Cancer Prev. 2014; 15(4):1823-9. DOI: 10.7314/apjcp.2014.15.4.1823. View

10.

Sprowl J, Ness R, Sparreboom A . Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet. 2012; 28(1):19-27. PMC: 3705946. DOI: 10.2133/dmpk.dmpk-12-rv-073. View

11.

Cormier C, Au K, Northrup H . A 10 bp deletion polymorphism and 2 new variations in the GLUT1 gene associated with meningomyelocele. Reprod Sci. 2010; 18(5):463-8. PMC: 3117222. DOI: 10.1177/1933719110388293. View

12.

Mullen S, Marini C, Suls A, Mei D, Della Giustina E, Buti D . Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. Arch Neurol. 2011; 68(9):1152-5. DOI: 10.1001/archneurol.2011.102. View

13.

Kishore B, Krane C, Di Iulio D, Menon A, Cacini W . Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int. 2000; 58(2):701-11. DOI: 10.1046/j.1523-1755.2000.00216.x. View

14.

Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

15.

Wang Y, Yin J, Li X, Chen J, Qian C, Zheng Y . The association of transporter genes polymorphisms and lung cancer chemotherapy response. PLoS One. 2014; 9(3):e91967. PMC: 3958404. DOI: 10.1371/journal.pone.0091967. View

16.

Liu W, Fang Y, Wang X, Liu J, Dan X, Sun L . Overcoming 5-Fu resistance of colon cells through inhibition of Glut1 by the specific inhibitor WZB117. Asian Pac J Cancer Prev. 2014; 15(17):7037-41. DOI: 10.7314/apjcp.2014.15.17.7037. View

17.

Efferth T, Volm M . Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther. 2005; 107(2):155-76. DOI: 10.1016/j.pharmthera.2005.02.005. View

18.

Wang Z, Xu B, Lin D, Tan W, Leaw S, Hong X . XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer. 2008; 62(1):99-104. DOI: 10.1016/j.lungcan.2008.02.019. View

19.

Amann T, Kirovski G, Bosserhoff A, Hellerbrand C . Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma. Mol Membr Biol. 2011; 28(3):182-6. DOI: 10.3109/09687688.2011.554447. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View